2024. Lenvatinib is More Effective & Safer Than Sorafenib in the Treatment of Renal Cell Carcinoma - A Single-Center Retrospective Analysis of 70 Cases. Journal of Carcinogenesis. 23, 1 (Dec. 2024), 624–628. DOI:https://doi.org/10.64149/J.Carcinog.23.1.624-628.